Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Genetic, Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

RADIAL is an algorithm which has been developed following a review of the literature on 67 autosomal recessive cerebellar ataxias (ARCA) and personal clinical experience. Frequency and specificity of each feature were defined for each autosomal recessive cerebellar ataxia, and corresponding prediction scores were assigned. Clinical and paraclinical features of patients are entered into the algorithm, and a patient's total score for each ARCA is calculated, producing a ranking of possible diagnoses. Sensitivity and specificity of the algorithm were assessed by blinded analysis of a multinational cohort of 834 patients with molecularly confirmed autosomal recessive cerebellar ataxia. The performance of the algorithm was assessed versus a blinded panel of autosomal recessive cerebellar ataxia experts. The correct diagnosis was ranked within the top 3 highest-scoring diagnoses at a sensitivity and specificity of \>90% for 84% and 91% of the evaluated genes, respectively. Mean sensitivity and specificity of the top 3 highest-scoring diagnoses were 92% and 95%, respectively. Our aim is now to validate in a prospective cohort of ARCA, the performance of RADIAL to predict the correct genetic diagnosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: t
View:

‣ \- For patients:

• Patient, male or female, over 5 years old (no upper age limit)

• Patient with cerebellar ataxia who started before the age of 40

• Patient with a family history compatible with autosomal recessive inheritance (sporadic case, consanguinity, several cases in siblings)

• Patient in which an acquired cause of cerebellar ataxia has been excluded

• Patient whose genetic diagnosis is unknown (NB: patients with a known negative result for the Friedreich's disease gene are eligible for inclusion))

• For patients over 18 years old: patient speaking and reading French, able to give a signed and dated informed consent to participate in the study.

• Patients who have reached the age of majority and whose DNA has been banked and who have signed a consent form authorizing the subsequent use of this DNA for research purposes, including genetic analysis of cerebellar ataxias or associated pathologies, and for whom the RADIAL information sheet can be completed in full, are eligible for inclusion.

• For patient under 18 years old: Tutor or person with parental authority must speak French and be able to give a signed and dated informed consent for the minor patient.

• Patients who are minors, whose DNA has been banked and for whom the parental authority has signed a consent form authorizing the subsequent use of this DNA for research purposes, including genetic analysis of cerebellar ataxias or associated pathologies, and for whom the RADIAL information sheet can be completed, are eligible.

• Patient affiliated to the French national health insurance

• \- For relatives:

• Male or female, over 18 years old (no upper age limit)

⁃ Biological father or mother of a patient included in RADIAL-VALID research protocol

⁃ (for prospective inclusion only) To be available for a visit to the participating center where the child is being followed

⁃ Speaking and reading French, able to give a signed and dated informed consent to participate in the study

⁃ Subject affiliated to the French national health insurance

Locations
Other Locations
France
CHU de Besancon- Neurology
RECRUITING
Besançon
CHU de Dijon- Neurology
RECRUITING
Dijon
CHU Lille- Neurology
NOT_YET_RECRUITING
Lille
CHU Marseille- Neurology
RECRUITING
Marseille
CHU Montpellier - Neurology
RECRUITING
Montpellier
CHU Nancy- Neurology
RECRUITING
Nancy
CHRU de Strasbourg - Neurology/Pediatrics
RECRUITING
Strasbourg
CHU Toulouse- Neurology
RECRUITING
Toulouse
Contact Information
Primary
Tranchant Christine, MD
christine.tranchant@chru-strasbourg.fr
+33 3 88 12 85 31
Time Frame
Start Date: 2021-09-20
Estimated Completion Date: 2029-09
Participants
Target number of participants: 400
Treatments
Experimental: experimental arm
The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:~* Control group: interpretation of genetic analyzes without the use of RADIAL;~* Experimental group: interpretation of genetic analyzes using RADIAL.~Genome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available.
Authors
Moreau Thibault
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov